Bovie Medical Corporation Announces Future Retirement of Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary
13 11월 2018 - 9:00PM
Business Wire
Bovie Medical Corporation (NYSE:BVX) (the “Company”), a
maker of medical devices and supplies and the developer of
J-Plasma®, a patented surgical product marketed and sold under the
Renuvion™ Cosmetic Technology brand in the cosmetic surgery market,
today announced that Jay D. Ewers, Chief Financial Officer,
Treasurer and Secretary, intends to retire.
The Company has initiated a search for a new Chief Financial
Officer and Mr. Ewers is committed to remaining in his current role
until a successor is found. Following the appointment of a
successor, Jay intends to continue to provide support in order to
facilitate an orderly transition.
“I would like to thank Jay, on behalf of the Board and the
entire team at Bovie Medical, for his significant contributions
since joining the Company in 2014,” said Charlie Goodwin, President
and Chief Executive Officer. “We appreciate his continued
commitment to the Company and its shareholders as we identify a
successor and wish him the very best in his future endeavors.”
“It has been a great pleasure to serve on the executive
leadership team at Bovie Medical and I’m proud of our many
accomplishments during my tenure,” said Jay Ewers Chief Financial
Officer, Treasurer and Secretary. “With the proceeds from the
recent strategic transaction, Bovie Medical is in a strong
financial position to pursue its future growth objectives, and I
believe this was the right time to begin my transition to
retirement.”
About Bovie Medical
Corporation:
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma® (marketed and
sold under the Renuvion™ Cosmetic Technology brand in the cosmetic
surgery market), a patented plasma-based surgical product for
cutting, coagulation and ablation of soft tissue. J-Plasma
technology utilizes a helium ionization process to produce a
stable, focused beam of plasma that provides surgeons with greater
precision, and minimal invasiveness. The new J-Plasma
handpieces with Cool-Coag™ technology deliver the precision of
helium plasma energy, the power of traditional monopolar
coagulation and the efficiency of plasma beam coagulation -
enabling thin-layer ablation and dissection and fast coagulation
with a single instrument, minimizing instrument exchange and
allowing a surgeon to focus on their patient and their procedures.
With Cool-Coag technology, the new J-Plasma handpieces can deliver
three distinctly different energy modalities - further increasing
the utility and versatility of the system. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company and its products, please
refer to the Bovie Medical Corporation website
at www.boviemedical.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company’s ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company’s filings with the Securities and Exchange
Commission including the Company’s Report on Form 10-K for the year
ended December 31, 2017 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181113005222/en/
Investor Relations
Contact:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino,
CFA443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Bovie (AMEX:BVX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024